Corium International Inc. (NASDAQ:CORI) has been given a $9.00 target price by research analysts at Jefferies Group in a research report issued to clients and investors on Thursday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Jefferies Group’s price target points to a potential upside of 63.34% from the stock’s previous close.
A number of other research analysts also recently commented on CORI. Zacks Investment Research downgraded shares of Corium International from a “hold” rating to a “sell” rating in a report on Tuesday, October 11th. FBR & Co set a $18.00 price target on shares of Corium International and gave the company a “buy” rating in a report on Friday, August 5th. Needham & Company LLC reaffirmed a “buy” rating and issued a $15.00 price target on shares of Corium International in a report on Monday, September 26th. Finally, Leerink Swann set a $16.00 price target on shares of Corium International and gave the company a “buy” rating in a report on Tuesday. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $12.25.
Corium International (NASDAQ:CORI) traded up 17.23% on Thursday, hitting $5.51. The company’s stock had a trading volume of 55,021 shares. The firm has a 50 day moving average of $5.02 and a 200 day moving average of $4.72. Corium International has a 12 month low of $3.14 and a 12 month high of $9.93. The firm’s market cap is $122.36 million.
A number of hedge funds have recently made changes to their positions in CORI. RTW Investments LLC increased its stake in shares of Corium International by 22.6% in the third quarter. RTW Investments LLC now owns 1,045,747 shares of the biopharmaceutical company’s stock valued at $5,888,000 after buying an additional 192,786 shares during the last quarter. Paloma Partners Management Co purchased a new stake in shares of Corium International during the second quarter valued at about $152,000. Finally, Opaleye Management Inc. increased its stake in shares of Corium International by 1.4% in the first quarter. Opaleye Management Inc. now owns 360,000 shares of the biopharmaceutical company’s stock valued at $1,390,000 after buying an additional 5,000 shares during the last quarter. 88.35% of the stock is owned by institutional investors and hedge funds.
Corium International Company Profile